Multicenter Expanded Access Protocol of Allogeneic Epstein-BarrVirus Cytotoxic T Lymphocytes (EBVCTLs)for Patients with EBV-Associated Lymphomas and Lymphoproliferative Disorders inImmunocompromised Patients for Whom There are No OtherComparable Options
|Effective start/end date||5/20/16 → 1/1/22|
- ATARA BIOTHERAPEUTICS, INC.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.